OBESITY PHARMACOTHERAPY: AN URGENT NEED FOR PROGRESSING SCIENCE, ACCESS, AND EQUITY—JACC: ADVANCES EXPERT PANEL

Descargar Publicación
Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial ARA II y BCC: la combinación antihipertensiva mejor tolerada